Pfizer lifts 2026 outlook amid Covid revenue drop

Pfizer (PFE) has increased its full-year 2026 revenue guidance to a range of $60.5 billion to $62.5 billion, lifting the midpoint by about $500 million. The revised outlook follows the company’s latest quarterly results and reflects management’s updated view of the business mix as pandemic-era contributions recede. The new range sets a clearer benchmark for Pfizer’s (PFE) medium-term performance as it leans more on its non-COVID portfolio and recently integrated assets.

By focusing investor attention on the 2026 target, Pfizer is framing expectations around a period when current cost programs and portfolio shifts are expected to be more fully reflected in its financials. The guidance range also serves as a reference point for assessing how successfully the company replaces declining COVID-related revenue with other therapies and franchises.

Management has announced an additional $2.5 billion in cost savings to be realized between 2027 and 2029. With this new tranche, Pfizer now expects total net savings of $9.7 billion through 2029. The cost measures are intended to streamline operations and support profitability as revenue growth becomes less dependent on COVID-related products.

These savings are planned over several years, indicating an extended period of efficiency efforts rather than a short, one-off program. The enlarged savings target is a key component of Pfizer’s strategy to manage earnings and cash flow while navigating a changing revenue base and investing in future growth areas.

Pfizer has guided its COVID-related products, including antiviral treatment Paxlovid and vaccine Comirnaty, to approximately $4 billion of annual revenue. This figure is described as a small fraction of the levels seen during the height of the pandemic. The reset underscores how sharply demand has normalized and how much less central COVID products have become to the company’s overall revenue mix.

The lower COVID contribution increases the importance of Pfizer’s broader portfolio and pipeline in sustaining growth toward its 2026 revenue targets. It also highlights why cost discipline and other strategic initiatives are being emphasized as the company moves through a post-pandemic adjustment period.

The company has flagged near-term uncertainty around its finance leadership, following the departure of CFO Dave Denton. A replacement announcement is expected in August, and the transition is being monitored as a key execution risk. Stable financial stewardship is important as Pfizer implements its long-term savings program and pursues its updated revenue objectives.

Despite the headwinds from lower COVID-related revenue and leadership changes, investor reaction to the latest updates has been measured but positive. Pfizer shares rose roughly 1.5% on the day the results were published and gained about 2.3% in the following session, trading near $26.20 intraday on August 7. The share moves suggest a cautious reception to the combination of higher guidance, expanded cost savings, and ongoing transition challenges.